



Biographies
Independent Citizens Oversight Committee
(Governing Board of the California Institute for Regenerative Medicine)

David Baltimore, Ph.D.

An executive officer from a California University (1 of 4)

David Baltimore, who has been the president of California Institute of Technology since 1997, was awarded the Nobel Prize at the age of 37 for research in virology. Baltimore has profoundly influenced national science policy on such issues as recombinant DNA research and the AIDS epidemic.

Baltimore's early investigations as a faculty member at Massachusetts Institute of Technology examined the molecular processes underlying the ability of poliovirus to infect cells, which led him to work on other RNA viruses and then to a consideration how cancer-causing RNA viruses manage to infect and permanently alter a healthy cell. He identified the enzyme reverse transcriptase, providing strong evidence for a process of RNA to DNA conversion, the existence of which had been hypothesized some years earlier. Baltimore and Howard Temin (with Renato Dulbecco, for related research) shared the 1975 Nobel Prize in Physiology or Medicine for their discovery, which has greatly expanded scientists' understanding of retroviruses such as HIV. He has contributed widely to the understanding of cancer, AIDS and the molecular basis of the immune response.

In the mid-1970s, Baltimore played an important role in creating a consensus on national science policy regarding recombinant DNA research. He served as founding director of the Whitehead Institute for Biomedical Research at MIT from 1982 until 1990. An early advocate of federal AIDS research, Baltimore co-chaired the 1986 National Academy of Sciences committee on a National Strategy for AIDS and was appointed in 1996 to head the National Institutes of Health AIDS Vaccine Research Committee.

Baltimore received a doctorate degree from Rockefeller University and a bachelor's degree in chemistry from Swarthmore College.

Robert Birgeneau, Ph.D.

An executive officer from a California University (2 of 4)

An internationally distinguished physicist, Robert Birgeneau, Ph.D., is chancellor of UC Berkeley. Birgeneau's research focuses on understanding the fundamental properties of materials beginning at the level of a single atom and building up to macroscopic dimensions. His work has earned him

numerous citations and awards, including the O.E. Buckley Prize of the American Physical Society and the H.E. Lilienfeld Prize of the American Physical Society.

A Toronto native and the first in his family to finish high school, Birgeneau received his B.Sc. in mathematics from the University of Toronto in 1963 and his Ph.D. in physics from Yale University in 1966. He served on the faculty of Yale for one year and then spent one year at Oxford University. He was a member of the technical staff at Bell Laboratories from 1968 to 1975 and then joined MIT as a professor of physics, spending 25 years on the faculty there. He was named head of the physics department in 1988 and in 1991 was appointed dean of science. He became the 14th president of the University of Toronto on July 1, 2000.

Birgeneau has been elected a foreign associate of the National Academy of Sciences, has received numerous awards for teaching and research, and is one of the most highly cited physicists in the world. He was elected a fellow of the Royal Society of London in 2001 and the Royal Society of Canada in 2002. A leader on gender issues within higher education, Birgeneau is well known for his commitment to diversity and equity in the academic community.

Keith L. Black, M.D.

An executive officer from a California Research Institute (1 of 4)

Dr. Keith L. Black serves as Director of Maxine Dunitz Neurosurgical Institute and Director of Neurosurgery at Cedars-Sinai Medical Center. An internationally renowned neurosurgeon and scientist, Dr. Black joined Cedars-Sinai Medical Center in July 1997 and was awarded the Ruth and Lawrence Harvey Chair in Neurosciences in November of that year. Prior to joining Cedars-Sinai, Dr. Black served on the University of California, Los Angeles faculty for 10 years as Professor of Neurosurgery. In 1992 he was awarded the Ruth and Raymond Stotter Chair in the Department of Surgery and was Head of the UCLA Comprehensive Brain Tumor Program.

Dr. Black pioneered research on designing ways to open the blood-brain barrier, enabling chemotherapeutic drugs to be delivered directly into the tumor. His work received the Jacob Javits award from the National Advisory Neurological Disorders and Stroke Council of the National Institutes of Health in June of 2000. Dr. Black and patients undergoing the first clinical trials of the drug, RMP-7, were profiled in 1996 on the PBS program, "The New Explorers," in an episode called "Outsmarting the Brain." His other groundbreaking research has focused on developing a vaccine to enhance the body's immune response to brain tumors, use of gene arrays to develop molecular profiles of tumors, the use of optical technology for brain mapping, and the use of focused microwave energy to non-invasively destroy brain tumors. He was featured on the cover of Time magazine in the Fall 1997 special edition of "Heroes in Medicine."

Dr. Black has a unique ability to combine cutting-edge research and an extremely busy surgical practice. Since 1987, he has performed more than 3,000 operations for resection of brain tumors. He has had a keen interest in science since childhood. At age 17, he published his first scientific paper, which earned the Westinghouse Science Award. He completed an accelerated college program at the University of Michigan and earned both his undergraduate and medical degrees in

six years. He completed his internship in general surgery and residency in neurological surgery at the University of Michigan Medical Center in Ann Arbor.

Susan V. Bryant, Ph.D.

An executive officer from a UC with a medical school (1 of 5)

Susan V. Bryant, Ph.D., is a developmental biologist who during her career has conducted influential research in the area of regeneration and has published more than 100 papers delineating its core principles in addition to pioneering the development of molecular techniques for studying regenerative systems.

Dean of the School of Biological Sciences at the University of California, Irvine (UCI), Dr. Bryant rose to the position after being the first woman in the university's history to be recruited as a faculty member in biology. Since then, she has continued to be a strong advocate for women in science, winning numerous awards including the UCI Pacesetter Award for contributions to women. Her goal as Dean is to ensure that the School is a major participant in the discoveries that are fueling the revolution in biology, and at the same time to work for the full participation of women and minorities in the scientific enterprise.

Dr. Bryant has been an influential developmental biologist, and she established regeneration as a model system for pattern formation. Her research provided evidence for a unified model for pattern formation, demonstrated the universality of regulative mechanisms among diverse animals, predicted the conservation of developmental pathways, and pioneered the development of molecular techniques for studying regenerating systems.

Dr. Bryant spent her childhood in Yorkshire, UK. She became interested in biology in at a girls-only high school, obtained her undergraduate degree at King's College and her Ph.D. degree at St. Mary's Hospital Medical School, University of London. She moved to the US to study regeneration as a postdoctoral fellow at Case Western Reserve University, after which she joined the faculty at UC Irvine. In 2005, she was elected a Fellow, the highest honor bestowed, by the Association for Women in Science.

Marcy Feit, RN, MSN

Patient Advocate (1 of 10)

Type II Diabetes

Marcy Feit joined ValleyCare Health System in 1973. After earning her RN credentials, she worked in the critical care unit for three years followed by a 3-year stint as the unit's head nurse. A series of promotions to administrative positions followed. In 1995, Marcy became Vice President of Patient Care Services. In December 1996, she became Chief Operating Officer and Interim Chief Executive Officer.

In July 1997, Marcy was appointed President and Chief Executive Officer of ValleyCare Health Systems.

She holds a Master's Degree in Nursing Science and Administration and has served on a state strategic planning committee for nursing, the Medical/Auxiliary Advisory Committee for Chabot College, and the Board of Directors for Hope Hospice. She is currently a member of the Tri-Valley Business Council, and serves as a member of the East Bay Hospital Council. She is also a member of the Board of Directors for Cooperative Hospitals, Inc., VHA West Coast, and Sigma Theta Tau, International.

Other accomplishments:

1998 Women of Achievement Award, Contra Costa County;
2003 San Francisco Times Top 100 Business Women of the Year
2003 Distinguished Alumna – Community College League of California
2004 Mertes-Feit Chabot Las Positas ValleyCare Education Center
2004 San Francisco Business Times Top 100 Business Women of the Year
2005 TriValley Magazine Ten Most Powerful Women

Michael A. Friedman, M.D.

An executive officer from a California Research Institute (2 of 4)

Dr. Michael Friedman is President and Chief Executive Officer of City of Hope, a cancer research and treatment institution dedicated to innovation in basic and clinical biomedical research and delivery of compassionate, world-class patient care. Dr. Friedman was formerly senior vice president of research and development, medical and public policy, for Pharmacia Corporation. In addition, he served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America following the events of September 11, 2001. Dr. Friedman had previously served as FDA Deputy Commissioner and was later tapped by the Clinton administration to serve as acting commissioner of the agency. He helped to streamline the FDA's review and approval process and provided oversight of evaluations for drugs, biologics, medical devices and food ingredients.

In 1983, Dr. Friedman was chief of the Clinical Investigations Branch of the Division of Cancer Treatment at the National Cancer Institute, and went on to become associate director of the Division's Cancer Therapy Evaluation Program. Before joining the NCI, Dr. Friedman spent nearly a decade at the University of California at San Francisco, serving as associate professor of medicine, eventually becoming interim director of the Cancer Research Institute.

Dr. Friedman has received numerous commendations, including the Surgeon General's Medallion in 1999. He received his Bachelor of Arts degree, magna cum laude, from Tulane University and a Doctorate in Medicine from the University of Texas. He completed postdoctoral training at Stanford University and the National Cancer Institute, and is board certified in Internal Medicine and Medical Oncology.

Michael D. Goldberg

An executive officer of a Commercial Life Science Entity (1 of 4)

As a general partner at MDV Michael leverages valuable entrepreneur and investor experience from his more than 20 years of work in the life sciences industry including biotechnology, pharmaceuticals, health services and healthcare information technology. In addition to pursuing life sciences investments for MDV he works to extend the firm's reach into major universities and research centers.

Prior to joining MDV Michael was Managing Director of Jasper Capital and Co-chair of the California Research and Cures Coalition (\$3 billion Prop 71 stem cell campaign). He has also held senior management and operations roles including serving as Chairman of OnCare, an oncology practice management company he founded in 1995. Until 1999 he also served as OnCare's Chief Executive Officer, where he guided revenue growth to \$100 million in three years.

Previously, Michael was Founder and Chief Executive Officer of Axion Inc., a cancer-focused healthcare service company he started in 1987 and sold to Bristol-Myers Squibb in 1996. Axion ranked number four on Inc. Magazine's list of the 500 fastest growing private companies in America for the five years ended 1994. Michael was also a recipient of Inc. Magazine's 1995 Entrepreneur of the Year Award. Prior to his tenure with Axion, Michael was a partner in the venture capital firm Sevin Rosen Funds, where he was responsible for the firm's investments in the biomedical industry.

Michael is a member of the executive committee of the board of trustees of the National Childhood Cancer Foundation and is on the Advisory Council of the Stanford Neuroscience Institute. He received a B.A. from Brandeis University and an M.B.A. from Stanford Graduate School of Business.

Brian E. Henderson, M.D.

An executive officer from a California University (3 of 4)

Brian E. Henderson, the holder of the Kenneth T. Norris Jr. Chair in Cancer Prevention, became dean of the Keck School of Medicine of USC on July 1, 2004.

Henderson is the founding chair of the Department of Preventive Medicine, was former director of the USC/Norris Comprehensive Cancer Center (1983) and the founding director of the Zilka Neurogenetic Institute (2002).

Henderson first came to the Keck School in 1970 as an associate professor of pathology. He established the Los Angeles Cancer Surveillance Program at USC in 1972 and the Hawaii-Los Angeles Multiethnic Cohort in 1993. He served as president of the San Diego-based Salk Institute for Biological Studies from 1993 to 1995, returning to USC in 1996.

Henderson's research focuses on the interconnection between environmental and genetic factors in the development, treatment and prevention of a wide variety of cancers.

Henderson was inducted into the Institute of Medicine of the National Academy of Sciences in 1992, and was awarded the Presidential Medallion, USC's highest honor, in 1999.

A native of California, Henderson received his undergraduate degree from the University of California at Berkeley, and his medical degree from the University of Chicago Medical School. He completed his internship and residency at Massachusetts General Hospital.

Edward W. Holmes, M.D.

An executive officer from a UC with a medical school (2 of 5)

Dr. Holmes was appointed Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of California, San Diego in the fall of 2000. He received a Doctor of Medicine degree from the University of Pennsylvania in 1967 and then pursued internal medicine training at the Hospital of the University of Pennsylvania and Duke University Medical Center. He joined the faculty at Duke University School of Medicine and was also appointed a Howard Hughes Medical Investigator in 1974. In 1991, he was recruited to the University of Pennsylvania School of Medicine to become the Chair of the Department of Medicine and the Frank Wister Thomas Professor of Medicine and Genetics.

In 1997, Dr. Holmes moved to Stanford University School of Medicine to become the Joseph Grant Professor in the School of Medicine, the Senior Associate Dean for Research, Vice President of Translational Medicine and Clinical Research, and Special Counselor to the President of the University on Biomedical Research. In January 1999, Dr. Holmes returned to Duke University as the Dean of the School of Medicine and Walter Kempner Professor in Medicine and Genetics.

Dr. Holmes engaged in basic biomedical and clinical research throughout his academic career, holding continuous NIH funding from 1975 through 2000, including a MERIT Award. His laboratory has focused on the molecular bases of human disease. He has been a national leader in developing innovative programs for training physician scientists and building translational medicine programs. He has served on numerous university and national advisory boards, including the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. Dr. Holmes has received the Distinguished Alumnus Awards from the University of Pennsylvania and Duke University, and has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, a Fellow of the American Association for the Advancement of Science, and a member of the Institute of Medicine of the National Academy of Sciences.

David A. Kessler, M.D.

An executive officer from a UC with a medical school (3 of 5)

David A. Kessler, MD, is the dean and vice chancellor for medical affairs at University of California San Francisco (UCSF) School of Medicine. Before joining UCSF in the fall of 2003, Dr. Kessler had been Dean of the Yale University School of Medicine since July 1997. Dr. Kessler,

who served as Commissioner of the United States Food and Drug Administration from November 1990 until March 1997, was appointed by President Bush and reappointed by President Clinton.

As Commissioner of the FDA, he acted to speed approval of new drugs and placed high priority on getting promising therapies for serious and life-threatening diseases to patients as quickly as possible. He introduced changes in the device approval process to make it more efficient and ensure that it meets high standards. Under his direction, the FDA announced a number of new programs, including: the regulation of the marketing and sale of tobacco products to children; nutrition labeling for food; user fees for drugs and biologics; preventive controls to improve food safety; measures to strengthen the nation's blood supply; and the MEDWatch program for reporting adverse events and product problems.

From 1984 until his FDA appointment, he was the medical director of the Hospital of the Albert Einstein College of Medicine in the Bronx, New York, where he held teaching appointments in the Department of Pediatrics and in the Department of Epidemiology and Social Medicine. From 1986 until 1990, Dr. Kessler also taught food and drug law at the Columbia University School of Law in New York. He was a consultant to the United States Senate Labor and Human Resources Committee from 1981 until 1984.

Dr. Kessler is a 1973 magna cum laude, Phi Beta Kappa graduate of Amherst College. He received his J.D. degree from The University of Chicago Law School, where he was a member of the Law Review, in 1978, and his M.D. degree from Harvard Medical School in 1979. He did his internship and residency in pediatrics at the Johns Hopkins Hospital. In 1986, he earned an Advanced Professional Certificate from the New York University Graduate School of Business Administration.

Robert Klein

Chair, Independent Citizens Oversight Committee

As the creator and primary backer of Proposition 71, which led to the creation of the California Institute for Regenerative Medicine (CIRM), Klein has been an instrumental figure in advocating for research and the development of cures for a variety of causes including Alzheimer's and diabetes, and was recently honored by *Time* magazine as one of the "100 Most Influential People of the Year" in 2005.

Bob is President of Klein Financial Corporation, a real estate investment banking consulting company focused on affordable housing finance and development with a record of approximately \$3 billion in financing and developing public and private projects. Bob served for 6 years as a Board Member for the State of California Housing Finance Agency which has approximately \$8 billion in finance outstanding, an AA S&P Bond rating and a history of receiving national awards in almost every category of affordable housing. This public corporation of the State of California was created by legislation in 1976, which Bob wrote as the principal consultant to the California State Assembly and State Senate Joint Committee on Housing and Urban Renewal.

Bob's commitment to advancing medical research originated in his youngest son Jordan's diagnosis with juvenile diabetes in 2001. In addition, his mother was diagnosed with Alzheimer's a year later; his father having died from heart disease over a decade earlier. In 2002, Bob was a principal negotiator, as a part of a JDRF team that worked successfully to pass a \$1.5 billion mandatory federal funding bill for an additional five years of Type 1 and Type 2 diabetes supplemental National Institutes of Health research funding. Bob currently serves on the board of the International Juvenile Diabetes Research Foundation.

Bob has a Bachelor of Arts in History with Honors from Stanford University and a Juris Doctorate from Stanford Law School.

Sherry Lansing

Patient Advocate (2 of 10)

Cancer

Founder and current chair of the Sherry Lansing Foundation, a philanthropic organization focusing on cancer research, health and education, Ms. Lansing was the chair of the Motion Picture Group of Paramount Pictures from 1992 to 2005, where she oversaw the release of more than 200 films including Academy Award winners *Forrest Gump*, *Braveheart*, and highest grossing movie of all time, *Titanic*. A pioneering studio executive, Lansing is the first woman in the film industry to oversee all aspects of a studio's motion picture production.

Her distinguished career has earned her numerous honors, including the Woodrow Wilson Award for Corporate Citizenship, the Milestone Award from the Producers Guild of America, the Overcoming Obstacles Achievement Award for Business, the YWCA Silver Achievement Award, the Outstanding Woman in Business Award from the Women's Equity Action League, the Distinguished Community Service Award from Brandeis University, the Alfred P. Sloan, Jr. Memorial Award and an honorary Doctorate in Fine Arts from the American Film Institute. She was also the recipient of the Simon Wiesenthal Center Distinguished Service Award for the Performing Arts and was named the 1996 Pioneer of the Year by the Foundation of the Motion Picture Pioneers. In 2004, Lansing received the Horatio Alger Humanitarian Award. Lansing serves on the Executive Committee of the Board of Directors of Friends of Cancer Research and as a Trustee of the American Association for Cancer Research. She continues to lend her energy and talents to such advisory boards and committees as the American Red Cross Board of Governors, the board of trustees for the Carter Center and Stop Cancer, a non-profit philanthropic group she founded in partnership with Dr. Armand Hammer.

Lansing is a Regent of the University of California and serves as chair of the University Health Services Committee. She graduated cum laude with a Bachelor of Science Degree from Northwestern University in 1966.

Gerald S. Levey, M.D.

An executive officer from a UC with a medical school (4 of 5)

Dr. Gerald S. Levey, a nationally recognized leader in both academic medicine and private sector medical affairs, is vice chancellor of medical sciences and dean of the David Geffen School of Medicine and holds the academic rank of professor of medicine in the department of medicine. As vice chancellor of medical sciences at UCLA he oversees a diverse medical enterprise including the School of Medicine, UCLA Medical Center, and the UCLA Neuropsychiatric Institute and Hospital.

Dr. Levey joined UCLA in September 1994, having previously served as senior vice president for medical and scientific affairs at Merck & Co., one of the world's leading pharmaceutical companies. He has held major leadership positions throughout his career, including serving as chair of the department of medicine at the University of Pittsburgh School of Medicine from 1979-1991. He is past president of the Association of Professors of Medicine, was a member of the Board of Governors of the American Board of Internal Medicine and is a member of the Association of American Physicians. Dr. Levey is a member of the medical honorary society Alpha Omega Alpha, and is a recipient of the Distinguished Alumnus Award from the University of Medicine and Dentistry of New Jersey and received his Mastership from the American College of Physicians in 1997.

Dr. Levey is an internist and endocrinologist widely known for his research on the thyroid gland and the heart. He was named a Howard Hughes Medical Institute Investigator while at the University of Miami from 1971-1978. Dr. Levey has developed a particular interest in issues of the nation's physician supply and the role of generalist physicians, and served as co-chair of the National Study of Internal Medicine Manpower from 1981-1991.

Ted W. Love, M.D.

An executive officer of a Commercial Life Science Entity (2 of 4)

Ted W. Love, M.D. was appointed president and chief executive officer of Nuvelo, Inc. in March 2001, having been appointed president and chief operating officer of the company in January 2001. He has served as a director of the company since February 2001.

Dr. Love joined Nuvelo from Advanced Medicine Inc., where he served as senior vice president of development from February 1998 to January 2001. Previously, Dr. Love spent six years at Genentech Inc., holding a number of senior management positions in Medical Affairs and Product Development. As vice president of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee.

Dr. Love earned his bachelor's degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, Dr. Love joined the faculty of Massachusetts General in the department of cardiology. He also serves as a member of the board of directors for both Predix Pharmaceuticals, Inc. and Santarus, Inc.

Richard A. Murphy, Ph.D.

An executive officer from a California Research Institute (3 of 4)

Richard A. Murphy became president and chief executive officer of the Salk Institute in October 2000. Prior to heading the Salk, for eight years he directed the Montreal Neurological Institute (MNI), a teaching and research institute of McGill University, where he was also professor of neurology and neurosurgery.

Dr. Murphy began his academic career at the Harvard University Medical School following postdoctoral studies at Massachusetts General Hospital. A member of Harvard's Department of Cell Biology and Anatomy from 1976 through 1986, he won numerous teaching awards and conducted an active research program in neurotrophins, proteins that promote the growth and survival of nerve cells and appear to play a role in memory.

He left Harvard in 1986 to chair the Department of Anatomy and Cell Biology at Canada's University of Alberta. While continuing his own research, he restructured that department and amassed a record of achievement that led to his appointment as MNI director.

At the Salk Institute, Dr. Murphy has worked with faculty and trustees to develop a strategic plan shaping the Institute's future scientific direction. Central to that plan is to broaden the Institute's current strengths through the hiring of a new generation of Salk scientists. Another priority has been to increase and enhance membership of the Salk's board of trustees to reflect the Institute's local, national, and international constituencies.

Dr. Murphy received his doctorate in Zoology at Rutgers University and a bachelor's degree from the College of the Holy Cross. He did post-doctoral work at Massachusetts General Hospital in Boston.

Tina S. Nova, Ph.D.

An executive officer of a Commercial Life Science Entity (3 of 4)

Dr. Nova is President, Chief Executive Officer, Co-Founder and a Director of Genoptix, Inc. Over the past several years she has been involved in the co-founding of three life science companies in the San Diego biotechnology community. Her current company, Genoptix, Inc., is a venture-backed biotechnology company developing advanced cellular isolation characterization techniques applicable in the post-genomics era.

She received a B.Sc. degree in Biological Sciences at the University of California, Irvine, where she graduated with Honors, and she received her Ph.D. in Biochemistry from the University of California, Riverside.

Dr. Nova serves on the Advisory Boards of the UC San Diego Division of Biological Sciences, the Keck Graduate Institute of Applied Life Sciences Advisory Council and UC Irvine Division of Biological Sciences. Additionally, she is on the Board of Trustees of University of San Diego. Dr.

Nova was the winner of the 2004 BIOCOM James McGraw Distinguished Contribution Award, the 2004 Distinguished Alumnus Award UC Riverside, the 2003 Distinguished Alumnus Award UC Irvine, the 2002 Outstanding Executive Award UC San Diego Jacobs School of Engineering and the 2001 Athena Pinnacle Award.

Ed Penhoet, Ph.D.

Vice Chair, Independent Citizens Oversight Committee

Edward E. Penhoet is currently the President of the Gordon and Betty Moore Foundation in San Francisco. Prior to becoming President, he served as the Foundation's Chief Program Officer for Science and Higher Education Programs.

Dr. Penhoet is the immediate past Dean of the School of Public Health and Professor of Public Health and of Molecular and Cell Biology at the University of California at Berkeley. Since 2000, he has been a director at Alta Partners, a pioneering venture capital firm that focuses on early-stage investing in life sciences, information technology and communications. He is also a director and co-founder of Chiron Corporation, one of the world's leading biotechnology companies. Dr. Penhoet served as Chiron's President and Chief Executive Officer from the time he co-founded the company in 1981 until April 30, 1998.

For 10 years prior to founding Chiron, Dr. Penhoet was a faculty member of the Biochemistry Department of the University of California, Berkeley. While at Chiron, he continued as an adjunct member of the faculty, teaching a variety of courses. In May 1991, Dr. Penhoet received the first Distinguished Faculty Award in the Life Sciences from the department of Molecular and Cell Biology at the University of California, Berkeley. In 1992, Dr. Penhoet shared with Dr. William J. Rutter, a Chiron co-founder, the Northern California Entrepreneur of the Year Award presented by Ernst & Young and Inc. Magazine; in 1994, Penhoet and Rutter received jointly the Harvard Business School Northern California Alumni Chapter award as Entrepreneur of the Year.

Dr. Penhoet earned his A.B. in biology from Stanford University in 1963, and his Ph.D. in biochemistry from the University of Washington in 1968. He was a post-doctoral fellow at the University of California, San Diego, from 1968 to 1970.

Phillip A. Pizzo, M.D.

An executive officer from a California University (4 of 4)

Philip A. Pizzo, MD, became dean of the Stanford School of Medicine in April 2001. Before joining Stanford, he was the physician-in-chief of Children's Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School. Pizzo is recognized for his contributions as a clinical investigator, especially in the treatment of children with cancer and HIV.

Pizzo received his undergraduate degree from Fordham University and an MD from the University of Rochester School of Medicine. He completed an internship and residency at Children's Hospital Medical Center in Boston, a teaching fellowship at Harvard Medical School, and a clinical and

research fellowship in pediatric oncology at the National Cancer Institute. Pizzo served as head of the institute's infectious disease section, chief of the NCI's pediatric department, and acting scientific director for NCI's Division of Clinical Sciences.

Pizzo devoted much of his distinguished medical career to the diagnosis, management, prevention and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. Pizzo and his research team pioneered the development of new treatments for children with HIV infection, lengthening and improving the quality of life for children with this disease. His research soon led to important clues about how to treat HIV-positive children and adults, and how to manage life-threatening infections. In 1988 Pizzo published the first article in the New England Journal of Medicine on antiviral therapy of HIV in children. He is also the author of more than 500 scientific articles and 14 books.

Pizzo has received several awards from the U.S. Public Health Service, including the Outstanding Service Medal in 1995. He has been cited in Best Doctors of America since 1995, and in 1990 was declared "Washingtonian of the Year" by Washingtonian Magazine for helping to found the Children's Inn, a temporary home for children undergoing treatment at the National Institutes of Health and their families.

Claire Pomeroy, M.D., M.B.A.

An executive officer from a UC with a medical school (5 of 5)

Claire Pomeroy, M.D, is Vice Chancellor for Human Health Sciences at UC Davis and Dean of the UC Davis School of Medicine, is an expert in infectious diseases and a professor of internal medicine and microbiology and immunology. She oversees the UC Davis Health System and all its academic, research and clinical programs, including the 800-member physician group known as UC Davis Medical Group and the 576-bed acute-care hospital known as UC Davis Medical Center. With an operating budget of nearly \$800 million, patient visits of nearly 900,000, and more than \$100 million in outside research funding, UC Davis Health System is a major contributor to the health care and economy of the Sacramento region.

Dr. Pomeroy joined UC Davis in 2003 as executive associate dean of the School of Medicine. In that role, she guided the development of a new strategic plan, enhanced the infrastructure for research and educational programs, and integrated the operations of the medical school and teaching hospital. Dr. Pomeroy leads an active research team studying host responses to infectious diseases. She has published over 100 articles and book chapters and edited two books. She currently serves on grant review study sections for the National Institutes of Health and the Department of Veterans Affairs.

With special expertise in HIV/AIDS, she is a long-time advocate for patients with HIV/AIDS and has a special interest in health-care policy. She also has led efforts to advance electronic health records to improve health-care quality. Dr. Pomeroy is a member of the Board of Directors of the MIND Institute at UC Davis and of the CARES clinic in Sacramento.

She received bachelor's and medical degrees from the University of Michigan, then completed her residency and fellowship training in internal medicine at the University of Minnesota. She also earned an MBA from the University of Kentucky.

Francisco J. Prieto, M.D.

Patient Advocate (3 of 10)

Type I Diabetes

Diabetes research expert, Francisco J. Prieto, M.D., serves as President of the Sacramento Sierra Chapter of the American Diabetes Association. He previously chaired the Association's Professional Education Committee and currently chairs the committee for "Tour de Cure", the ADA's annual bicycling event. He has been active in Diabetes care, patient and professional education and exercise promotion throughout his career.

Dr. Prieto was born in Chicago Illinois, one of 9 children of Jorge Prieto MD and Luz Maria Prieto. He received his Bachelor of Sciences with majors in Biology and History from the University of Illinois – Chicago, where he was undergraduate representative on the UIC Chancellor Search Committee. He received his M.D degree from the university of Minnesota, then completed a residency in Family Medicine at the University of Arizona. He served 3 years in the National Health Service Corps, and was an Associate Clinical Professor at the Univ. of Arizona.

Dr. Prieto practices with Sutter Medical Group in Elk Grove, and is an assistant Clinical Professor at the Univ. of California, Davis.

John C. Reed, M.D.

An executive officer from a California Research Institute (4 of 4)

Dr. John C. Reed is President & Chief Executive Officer of the Burnham Institute, a non-profit biomedical research institute with over 600 employees. Dr. Reed received his undergraduate education from the University of Virginia (BA/Biochemistry), where he graduated Phi Beta Kappa in 1980, then entered the Medical School of the University of Pennsylvania (MD, PhD), where he graduated in Alpha Omega Alpha in 1986.

In 1992, Dr. Reed joined the Burnham Institute, and was promoted to Scientific Director in 1995, prior to becoming President & CEO in 2002. He conceived of and was instrumental in launching the formation of a new research center at the Burnham Institute devoted to research on aging and neurodegenerative diseases. Dr Reed also served as Deputy Director of the Burnham Institute's NCI sponsored Cancer Center from 1994 to 2002, and briefly as interim Director in 2002. He additionally holds adjunct Professorships at the University of California San Diego and San Diego State University.

Dr. Reed remains an active scientist, currently directing a laboratory of ~40 persons at the Burnham Institute. His research interests have focused primarily on cancer, but he has also made important contributions in the areas of AIDS, autoimmunity, stroke and other diseases. He has been a pioneer

in delineating the fundamental mechanisms that regulate programmed cell death, a process by which cells in the body commit suicide through activation of a genetically controlled program. He has the distinction of having published more papers on programmed cell death (also known as “apoptosis”) during the past decade than any other scientist worldwide, according the Institute for Scientific Information.

Dr. Reed currently serves on the editorial boards of over 12 scientific journals. He has also served as an advisor to the National Cancer Institute (NCI), American Cancer Society (ACS), and the American Association for Cancer Research (AACR). He is the recipient of numerous awards for his research accomplishments, and has been awarded over 65 research grants by a variety of funding agencies, including the National Institutes of Health, the NCI, the ACS, the Leukemia Society of America, CaP-CURE, ABC2, and the Susan B Komen Breast Cancer Foundation.

Joan Samuelson, J.D.

Patient Advocate (4 of 10)

Parkinson’s Disease

Diagnosed with Parkinson's in 1987, Ms. Samuelson left the practice of law to found the Parkinson's Action Network in 1991, and continues to serve as President and a member of the executive committee of the Board of Directors. PAN is credited with many successes in increasing federal research spending, including the 1997 Morris K. Udall Parkinson’s Research Act. Samuelson played an active role in the campaign resulting in the 2004 passage of California’s Proposition 71 Stem Cell Research and Cures Act.

Samuelson has been appointed to a variety of advisory panels on biomedical research and health policy. She served as an Independent Report Reviewer for the 2004 Report of the National Academies’ of Science’s Institute of Medicine on NIH Extramural Centers Programs, and sits on the Advisory Committee to the Director, National Institute of Environmental Health Sciences. In 2004 she was appointed Patient Advocate to the Medicare Consumer Advisory Committee. She serves on the NIEHS Collaborative Center for Parkinson’s Disease Environmental Research and the Environmental and Occupational Health Sciences Institute at UMDNJ/Robert Wood Johnson Medical School. Samuelson is a longtime member of the American Society for Neural Transplantation and Repair.

Samuelson was honored by the American Society for Neural Transplantation in 1997 for "outstanding efforts and support for research," and received Research!America's 2000 advocacy award for "Exceptional Contributions as a Volunteer Advocate for Medical Research.” She is a graduate of the University of California at Los Angeles (B.A. Public Service, 1972) and the Boalt Hall School of Law at the University of California at Berkeley (J.D., 1977). Before founding PAN, her law practice specialized in litigation and alternative dispute resolution.

David Serrano Sewell, J.D.

Patient Advocate (5 of 10)

MS/ALS

A Los Angeles native, David was raised in a household that valued public service, volunteer work, and political involvement. David has commented that “those early experiences were important, they taught me the value of caring for others, hard work, and loyalty.”

Currently, David is employed as a Deputy City Attorney in the S.F. City Attorney’s Office, assigned to the Port of San Francisco. In this capacity, David advises the Port on transactional, land use, permitting, and trust law.

Moving to San Francisco in 1989 to attend San Francisco State University, he served as Student Body President in 1993.

David is a veteran of numerous local and statewide campaigns. In 1995, he served as an aide to Mayor Willie L. Brown, Jr., working on land use and permitting issues. In time, he decided to attend Golden Gate University School of Law. During law school, he was a member of Law Review, was awarded the Witkin and Cali Award in Federal Administrative Law, was as an extern in the chambers of Judge Maxine M. Chesney, U.S. District Court, Northern District of California. He was admitted to the State Bar in June, 2003.

He has served on the City’s Ethic’s and Elections commission, respectively, and the board of directors of BRAVA! For Women in Arts, a community based theatre group focusing on Latina playwrights.

After his own diagnosis of MS, he began volunteering with the Northern California Chapter of the National Multiple Sclerosis Society, assisting the organization in their advocacy efforts. David firmly believes “that advocacy is crucial to ensuring that precious research dollars are spent in a manner that will benefit patients.

Jeff Sheehy

Patient Advocate (6 of 10)

HIV/AIDS

Jeff Sheehy is director for communications at the AIDS Research Institute at UCSF. He is a longtime HIV/AIDS and gay civil rights activist and a person living with HIV. Sheehy most notably worked on Survive AIDS’ project advocating for organ transplants for people with HIV. Survive AIDS, in collaboration with Assemblywoman (now Senator) Carole Migden, obtained funds for organ transplants for people with HIV. This initiative has not only saved lives of Californians with HIV/AIDS who needed transplants, but also led to a NIH funded protocol that is performing solid organ transplants in people with HIV at sites across the country.

In 1996, he and two colleagues conceived, drafted and lobbied through San Francisco’s historic Equal Benefits Ordinance, which requires that companies contracting with the City provide the domestic partners of employees the same benefits that spouses of employees receive. To support the legislation, he founded and led Equal Benefits Advocates, which conducted the successful national boycott of United Airlines that resulted in United, American, and US Airways offering domestic

partner benefits to their employees worldwide in 1999. To date, over 3,500 companies have complied with the law. And, an estimated 50,000+ lesbians and gay men around the country have now obtained health insurance and other benefits for their domestic partners due to this law.

From 1998 to 2000, Sheehy served as a victim advocate for the San Francisco District Attorney. In that position, he assisted same-sex victims of domestic violence and hate crimes and conducted an advanced officer training class in same-sex domestic violence at the San Francisco Police Academy. Sheehy was appointed HIV/AIDS advisor to San Francisco Mayor Gavin Newsom in 2004.

Sheehy has been the recipient of the Cape Crusader Award from Equality California, the HRC Leadership Award from The Human Rights Campaign, the Tomas Fabregas AIDS Hero Award presented at San Francisco's AIDS Candlelight March in 2001 and was featured in OUT Magazine's OUT 100 list of the most influential members of the LGBT community in 1999. He received a bachelor's degree in history from the University of Texas in Austin.

Jonathan Shestack

Patient Advocate (7 of 10)

Mental Health

Jonathan Shestack is the founder of Cure Autism Now (CAN), the largest provider of support for autism research and resources in the country. Founded in 1995, CAN is a nonprofit organization of parents, clinicians and leading scientists committed to accelerating the pace of biomedical research in autism. Since its founding, CAN has committed more than \$12 million to research, the establishment and ongoing support of the Autism Resource Exchange (AGRE), and numerous outreach and awareness activities aimed at families, physicians, governmental officials and the general public.

Shestack is currently vice president of Cure Autism Now.

Oswald Steward, Ph.D.

Patient Advocate (8 of 10)

Spinal Cord Injury

Oswald Steward, Ph.D., is known for his research on how nerve cells create and maintain their connections with each other, and how these synapses are modified after injury. He has also conducted research on how genes influence nerve cell regeneration, growth and function and how physiological activity affects nerve cell connections.

Dr. Steward is currently the chair and director of the Reeve-Irvine Research Center for Spinal Cord Injury at the University of California, Irvine (UCI) and also professor of anatomy and neurobiology. He serves on the board of the Christopher Reeve Paralysis Foundation and also serves as the chair of its Science Advisory Council. Dr. Steward was also the chair of a National Institutes of Health (NIH) neurobiology review group and served on the NIH's Spinal Cord Injury Planning Committee. Prior to joining the faculty at UC Irvine, he was Professor of Neuroscience and Neurosurgery at the University of Virginia, where he served as Chair of the Department of Neuroscience.

Steward is a recipient of the NIH Research Career Development Award, the Jacob Javitz Neuroscience Investigator Award and the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression. He earned a doctorate degree in psychobiology from the University of California, Irvine and a bachelor's degree in psychology from the University of Colorado, Boulder.

Leon J. Thal, M.D.

Patient Advocate (9 of 10)

Alzheimer's Disease

Leon J. Thal, M.D., leads a national consortium of more than 80 centers called the Alzheimer's disease Cooperative Study, which are funded by a grant from the National Institute of Health on Aging to test promising drugs for Alzheimer's disease quickly and efficiently. His current research interests focus on three areas: the effects of basal forebrain lesion-induced memory loss, clinical pathological correlations in Alzheimer's disease (AD), and the conduct of clinical drug trials in AD.

Dr. Thal is currently the chair and professor of the department of neurosciences at the University of California, San Diego (UCSD) and the director of the Alzheimer's disease Research Center at UCSD. He is also an advisor on the Federal Drug Administration's (FDA) Alzheimer Assessment Team and is a member of many medical associations and boards, including the San Diego chapter of the Alzheimer's Association. He has served as chairman of FDA Peripheral and Central Nervous System Drugs Advisory Committee and the Clinical Trial Subcommittee for the Alzheimer's disease Research Centers.

Dr. Thal has received numerous honors and awards and has extensive experience as a grant reviewer. He earned his medical degree from Downstate Medical Center, State University of New York and a bachelor's degree from Tufts University.

Janet S. Wright, M.D., F.A.C.C.

Patient Advocate (10 of 10)

Heart Disease

Janet S. Wright M.D., F.A.C.C., is currently assisting in the coordination of the American College of Cardiology's (ACC) collaboration with several disease management organizations in Phase I of CMS' Chronic Care Improvement Programs (CCIP). Her interest in disease management led to her contribution in "Specialty Referral Guidelines for Cardiovascular Evaluation and Management" and "Defining the Patient-Physician Relationship for the 21st Century," both of which are collaborative efforts of American Healthways and Johns Hopkins University.

Dr. Wright practices invasive cardiology as a partner in Northstate Cardiology Consultants in Chico, California and currently serves on the board of trustees of the American College of Cardiology (ACC). She is the ACC Advocacy Committee's Liaison to the Food and Drug Administration and to the American Association of Cardiovascular and Pulmonary Rehabilitation.

Dr. Wright was recently elected to the board of directors of the Disease Management Association of America (DMAA) and is a member of the DMAA Healthcare Leadership Advisory Council.

Dr. Wright received her medical doctorate at the University of Tennessee and completed her internal medicine residency at Children's Hospital and Adult Medical Center in San Francisco. She also completed a cardiovascular fellowship at San Francisco General Hospital and the University of California, San Francisco.

#